Acute Gout Flares, Genetics, and Long-Term Treatment: Where KRYSTEXXA Fits

Gout often announces itself dramatically: a person goes to bed feeling well and wakes with a big toe joint that is red, hot, swollen, and so tender that even a bedsheet hurts. This classic presentation is called podagra, but gout can also affect the ankle, midfoot, knee, fingers, and other joints.

The pain comes from an intense inflammatory response to monosodium urate crystals. These crystals form when urate levels remain high enough for long enough to collect in and around joints. Treating the painful flare matters, but lasting control requires a second strategy: lowering the body's urate burden so the crystals can gradually dissolve.

What to do during a suspected acute gout flare

Seek prompt evaluation for a first attack or for any joint that becomes suddenly red, hot, and swollen. Gout may resemble a bacterial joint infection, cellulitis, a fracture, or another form of inflammatory arthritis. Fever, chills, an open wound, red streaking, immune suppression, or feeling systemically ill makes urgent assessment especially important.

When gout is the likely diagnosis, treatment works best when started early. A clinician may select one of the following based on kidney function, stomach-ulcer or bleeding history, diabetes, heart disease, medication interactions, and how many joints are involved:

• Colchicine: Most effective when taken early. Dose adjustments or avoidance may be necessary with kidney or liver disease and certain interacting medications.
• Nonsteroidal anti-inflammatory drugs (NSAIDs): Medicines such as naproxen may help appropriate patients, but are not safe for everyone, particularly those with kidney disease, ulcers, bleeding risk, or certain cardiovascular conditions.
• Corticosteroids: Oral medication or an injection may be used when colchicine or NSAIDs are unsuitable. Infection should be excluded before injecting a joint.

Resting and elevating the foot, applying a wrapped cold pack for short intervals, staying hydrated, and avoiding pressure from tight shoes can provide additional relief. Do not begin aspirin for a flare, and do not change prescribed diuretics or other medicines without the prescribing clinician.

If you already take allopurinol, febuxostat, or another daily urate-lowering medicine, it is usually continued during the flare. Abruptly stopping it can cause urate levels to fluctuate. The flare itself is treated with anti-inflammatory medication.

Why gout runs in families

Gout is sometimes portrayed as the result of overindulgence, but that explanation is incomplete and often unfair. In most people with gout, the main problem is underexcretion: the kidneys and intestines do not eliminate enough urate for the amount the body produces.

Urate handling is partly inherited. Research has identified variants in transport-related genes including SLC2A9 and ABCG2 that influence how urate is moved through the kidneys or intestine. Other genes also contribute, and no single variant determines a person's future. A family history represents a predisposition, not a certainty, and routine consumer genetic testing is not required to diagnose or manage most gout.

Inherited susceptibility can combine with chronic kidney disease, high blood pressure, insulin resistance, obesity, dehydration, menopause, alcohol, fructose-sweetened drinks, or purine-rich foods. Certain medicines, including thiazide and loop diuretics, cyclosporine, tacrolimus, and low-dose aspirin, may also raise urate. These medications may still be medically necessary, so changes should be coordinated with the prescribing clinician.

Long-term management: treat the urate, not only the attacks

Repeatedly treating pain without reducing the urate burden allows crystals to remain. Over time, attacks may become more frequent, symptom-free intervals may shorten, and firm deposits called tophi can damage joints, tendons, skin, and bone.

Long-term urate-lowering therapy is commonly recommended for patients with tophi, gout-related joint damage, or frequent flares. It may also be considered after a first flare when substantial kidney disease, kidney stones, or very high serum urate is present. The decision should be individualized.

Allopurinol is generally the preferred first-line urate-lowering medicine, including for many people with chronic kidney disease, with a low starting dose and gradual adjustment. Febuxostat is another xanthine oxidase inhibitor used in selected patients. Other approaches may be appropriate depending on kidney function, stone history, medication tolerance, and response.

Treatment follows a treat-to-target approach rather than a fixed dose for everyone. A common serum urate goal is below 6 mg/dL; a lower goal may be used for severe tophaceous disease. Levels are checked during dose adjustment and periodically thereafter.

Paradoxically, flares can temporarily increase when urate-lowering treatment begins because old deposits are shifting. Low-dose colchicine, an NSAID, or another anti-inflammatory strategy is often prescribed for at least the first several months. This does not mean the urate-lowering medicine is failing.

Lifestyle helps, but gout is not a failure of willpower

Weight management when appropriate, good hydration, limiting beer and distilled spirits, reducing fructose-sweetened drinks, and moderating organ meats, large portions of red meat, and certain shellfish can reduce risk. Low-fat dairy, vegetables, and an overall heart-healthy eating pattern can support metabolic health.

However, diet alone often lowers urate only modestly and may not replace medication when crystal deposits are established. The goal is a sustainable plan, not blame or an excessively restrictive “gout diet.” Managing blood pressure, kidney disease, diabetes, cholesterol, sleep apnea, and cardiovascular risk is also part of comprehensive gout care.

What is KRYSTEXXA, and who may need it?

KRYSTEXXA (pegloticase) is not a routine treatment for a first gout attack. It is an intravenous biologic medicine for adults with uncontrolled gout whose disease has not responded adequately to standard oral urate-lowering medicines, who cannot tolerate them, or for whom those treatments are not appropriate.

Pegloticase is a modified uricase enzyme. Humans do not naturally have functional uricase; the medication converts uric acid into allantoin, which is more soluble and easier to eliminate. This can reduce urate rapidly and may shrink tophi over time.

Treatment is generally given by intravenous infusion every two weeks in a monitored healthcare setting. Current practice often combines pegloticase with an immunomodulator such as methotrexate when appropriate, because this can reduce anti-drug antibody formation and improve the chance of a sustained response.

Important KRYSTEXXA safety steps

• Patients need testing for G6PD deficiency before treatment because pegloticase can cause dangerous hemolysis or methemoglobinemia in affected individuals.
• Infusion reactions and anaphylaxis can occur. Premedication and observation are required, and treatment must be given where these reactions can be managed.
• Serum urate is checked before infusions. A rise above 6 mg/dL, particularly on two consecutive checks, can indicate loss of response and a higher reaction risk, prompting discontinuation.
• Oral urate-lowering medicines are generally stopped before KRYSTEXXA and not used concurrently because they can mask the urate rise used to identify loss of response.
• Patients with congestive heart failure require careful risk assessment and monitoring.

Flares may increase early in KRYSTEXXA treatment as deposits begin to mobilize, so preventive anti-inflammatory therapy is commonly used. Eligibility, accompanying immunomodulator therapy, laboratory monitoring, and infusion safety are typically coordinated with a rheumatologist or another clinician experienced in advanced gout treatment.

A podiatric evaluation can protect the joint

Acute big toe or foot pain deserves an accurate diagnosis, especially during a first episode. Vertex Podiatry can evaluate the painful joint, consider imaging or aspiration when appropriate, help control the acute inflammation, and coordinate long-term medical management when recurrent or advanced gout requires broader care.

Learn more about gout affecting the foot and ankle. For a sudden painful, red, or swollen foot joint, call (614) 328-5561 or request an appointment online.